Stocks and Investing Stocks and Investing
Fri, April 17, 2020

Matt Miksic Maintained (ABT) at Buy with Increased Target to $106 on, Apr 17th, 2020


Published on 2024-10-27 03:17:42 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Credit Suisse, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $95 to $106 on, Apr 17th, 2020.

Matt has made no other calls on ABT in the last 4 months.



There are 7 other peers that have a rating on ABT. Out of the 7 peers that are also analyzing ABT, 4 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Decreased Target to $93 on, Wednesday, April 8th, 2020
  • Amit Hazan of "Goldman Sachs" Initiated at Hold and Held Target at $96 on, Thursday, February 13th, 2020
  • Marie Thibault of "BTIG" Initiated at Hold on, Thursday, February 6th, 2020
  • Christopher Pasquale of "Guggenheim" Downgraded from Strong Buy to Hold on, Thursday, January 2nd, 2020


These are the ratings of the 3 analyists that currently disagree with Matt


  • Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $101 on, Thursday, April 16th, 2020
  • David Lewis of "Morgan Stanley" Maintained at Buy with Decreased Target to $96 on, Friday, March 27th, 2020
  • Joanna Wiensch of "Citigroup" Initiated at Strong Buy and Held Target at $96 on, Thursday, March 5th, 2020
Contributing Sources